1-(2,3-二氢-1,4-苯并二噁英-6-甲基)哌嗪 | 67869-88-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 中文名称: 1-(2,3-二氢-1,4-苯并二噁英-6-甲基)哌嗪
• 英文名称: 3,4-Aethylendioxy-benzyl-piperazin
• 英文别名: 1-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-piperazine；4-[(2,3-dihydrobenzo-1,4-dioxin-6-yl)methyl]piperazine；1-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)piperazine；1-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)piperazine
• CAS: 67869-88-9
• 化学式: C₁₃H₁₈N₂O₂
• mdl: MFCD06655689
• 分子量: 234.298
• InChiKey: PQDMWCAXHTUPRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  33.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  1-(2,3-二氢-1,4-苯并二噁英-6-甲基)哌嗪 生成 4-[(2,3-Dihydrobenzo-1,4-dioxin-6-yl)methyl]-1-[(indan-2-yl)methyl]piperazine
  参考文献：
  名称：

  Piperazine, piperidine and 1,2,5,6-tetrahydropyridine

  摘要：

  从以下式中选择的化合物：##STR1## 其中：A-B，n，D和E如规范中定义，它们的外消旋混合物，以及它们的光学异构体，以及与适当酸的生理耐受盐。本发明的产品可用于治疗。

  公开号：

  US05684020A1
• 作为产物：
  描述：

  在 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 作用下， 以 甲醇 、 乙二醇 为溶剂， 反应 5.0h， 生成 1-(2,3-二氢-1,4-苯并二噁英-6-甲基)哌嗪
  参考文献：
  名称：

  抗结核苄基哌嗪脲的设计、合成及SAR

  摘要：

  摘要 GSK Tres Cantos 的科学家披露的N-糠基哌嗪脲被选为来自表型全细胞筛选的抗分枝杆菌。用苯环取代 GSK Tres Cantos 分子中的呋喃环产生的分子 ( I ) 对Mtb H37Rv 的 MIC 为 1 μM，细胞毒性低（HepG2 IC 50  ~ 80 μM），良好的 DMPK 特性和特异性山地车_ 为了描绘与 ( I ) 相关的 SAR，合成了 55 种类似物并针对Mtb进行了筛选. SAR 表明哌嗪环、苄基脲和胡椒基部分是该系列的基本特征。该系列中的活性化合物代谢稳定，细胞毒性低，是优化的宝贵线索。分子对接表明这些分子像 Q203 一样占据 QcrB 的 Q0 位点。 图形摘要 N-糠基哌嗪-1-羧酰胺的生物等排替代产生了分子 (I) 一种具有令人满意的 PD、代谢和毒性特征的新型先导。

  DOI：

  10.1007/s11030-020-10158-3

文献信息

• Discovery of talmapimod analogues as polypharmacological anti-inflammatory agents
  作者：Wandong Liu、Caiyun Hou、Jiaming Li、Xiaodong Ma、Yanchun Zhang、Mengqi Hu、Yuanzheng Huang

  DOI：10.1080/14756366.2019.1693703

  日期：2020.1.1

  Twenty novel talmapimod analogues were designed, synthesised and evaluated for the in vivo anti-inflammatory activities. Among them, compound 6n, the most potent one, was selected for exploring the mechanisms underlying its anti-inflammatory efficacy. In RAW264.7 cells, it effectively suppressed lipopolysaccharides-induced (LPS-induced) expressions of iNOS and COX-2. As illustrated by the western blot

  设计，合成和评估了二十种新的talmapimod类似物的体内抗炎活性。其中，选择最有效的化合物6n来探索其抗炎功效的潜在机制。在RAW264.7细胞中，它有效地抑制了脂多糖诱导的（LPS诱导的）iNOS和COX-2的表达。如蛋白质印迹分析所示，6n下调了NF-κB信号转导和p38 MAPK磷酸化。进一步的酶法分析确定6n是对p38αMAPK（IC50 = 1.95 µM）和COX-2（IC50 = 0.036 µM）的有效抑制剂。由于同时抑制p38αMAPK，其上游效应物和COX-2以及下调NF-κB和MAPK信号通路的能力6n（一种多药理抗炎剂），
• DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS
  申请人：Matsuyama Hironori

  公开号：US20100004438A1

  公开（公告）日：2010-01-07

  An object of the present invention is to provide a medicinal drug much improved in anti tumor activity and excellent in safety. According to the present invention, there is provided a medicinal drug containing a compound represented by the following general formula (1) or a salt thereof as an active ingredient: [Formula 1] wherein X 1 represents a nitrogen atom or a group —CH═, R 1 represents a group -Z-R 6 , in which Z represents a group —CO—, a group —CH(OH)— or the like, R 6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R 2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents [Formula 2] wherein R 3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R 4 represents an imidazolyl lower alkyl group or the like.

  本发明的一个目的是提供一种在抗肿瘤活性方面大大改进且安全性优异的药物。根据本发明，提供了一种包含以下一般式（1）所表示的化合物或其盐作为活性成分的药物：[式1]其中X1代表氮原子或基团—CH═，R1代表一个基团-Z-R6，其中Z代表基团—CO—，基团—CH(OH)—或类似的基团，R6代表一个含有1至4个氮原子、氧原子或硫原子的5至15个成员的单环、双环或三环饱和或不饱和杂环基团，R2代表氢原子或卤原子，Y代表基团—O—，基团—CO—，基团—CH(OH)—或低碳烷基基团，A代表[式2]其中R3代表氢原子、低碳氧基基团或类似基团，p代表1或2，R4代表咪唑基低碳基团或类似基团。
• Aromatic Compounds
  申请人：Fukushima Tae

  公开号：US20070270422A1

  公开（公告）日：2007-11-22

  The present invention provides a novel compound, which has an excellent effect of suppressing the generation of collagen and less side effects, with being excellent in terms of safety. The compound of the present invention is represented by the following general formula (1): [wherein X 1 represents a nitrogen atom or a group —CH═; R 1 represents a group -Z-R 6 , wherein Z represents a group —CO—, a group —CH(OH)—, or the like, and R 6 represents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; R 2 represents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group —O—, a group —CO—, a group —CH(OH)—, a lower alkylene group, or the like; and A represents a group or the like, wherein R 3 represents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and R 4 represents an imidazolyl lower alkyl group or the like.

  本发明提供了一种新型化合物，具有抑制胶原生成的优异效果，并且具有较少的副作用，在安全性方面表现出色。本发明的化合物由以下通式（1）表示：[其中X1代表氮原子或基团—CH═；R1代表基团-Z-R6，其中Z代表基团—CO—、基团—CH(OH)—或类似基团，而R6代表具有1到4个氮原子、氧原子或硫原子的5-到15元的单环、双环或三环、饱和或不饱和杂环基团；R2代表氢原子、卤素原子或低碳链基团；Y代表基团—O—、基团—CO—、基团—CH(OH)—、低碳链基团或类似基团；A代表基团或类似基团，其中R3代表氢原子、低碳醚基团或类似基团，p代表1或2，而R4代表咪唑基低碳基团或类似基团。
• Aromatic compounds for suppressing the generation of collagen
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US08188277B2

  公开（公告）日：2012-05-29

  The present invention provides a novel compound, which has an excellent effect of suppressing the generation of collagen and less side effects, with being excellent in terms of safety. The compound of the present invention is represented by the following general formula (1): [wherein X1 represents a nitrogen atom or a group —CH═; R1 represents a group —Z—R6, wherein Z represents a group —CO—, a group —CH(OH)—, or the like, and R6 represents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; R2 represents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group —O—, a group —CO—, a group —CH(OH)—, a lower alkylene group, or the like; and A represents a group or the like, wherein R3 represents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and R4 represents an imidazolyl lower alkyl group or the like.

  本发明提供了一种新型化合物，其在安全性方面表现优异，具有抑制胶原生成的出色效果和较少的副作用。本发明的化合物由以下通式（1）表示：[其中X1表示氮原子或基团—CH═；R1表示基团—Z—R6，其中Z表示基团—CO—、基团—CH（OH）—或类似物，R6表示具有1至4个氮原子、氧原子或硫原子的5至15个成员的单环、双环或三环、饱和或不饱和杂环基团；R2表示氢原子、卤原子或较低的烷基；Y表示基团—O—、基团—CO—、基团—CH（OH）—、较低的烷基或类似物；A表示基团或类似物，其中R3表示氢原子、较低的烷氧基或类似物，p表示1或2，R4表示咪唑基较低烷基基团或类似物。
• Diarylether derivatives as antitumor agents
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US08236826B2

  公开（公告）日：2012-08-07

  An object of the present invention is to provide a medicinal drug much improved in anti tumor activity and excellent in safety. According to the present invention, there is provided a medicinal drug containing a compound represented by the following general formula (1) or a salt thereof as an active ingredient: [Formula 1] wherein X1 represents a nitrogen atom or a group —CH═, R1 represents a group —Z—R6, in which Z represents a group —CO—, a group —CH(OH)— or the like, R6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents [Formula 2] wherein R3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R4 represents an imidazolyl lower alkyl group or the like.

  本发明的目的是提供一种在抗肿瘤活性方面得到显著改善且安全性优异的药物。根据本发明，提供了一种含有以下通式（1）所代表的化合物或其盐作为活性成分的药物：[公式1] 其中，X1代表氮原子或基团-CH═，R1代表基团-Z-R6，其中Z代表基团-CO-、基团-CH（OH）-或类似的基团，R6代表具有1到4个氮原子、氧原子或硫原子的5至15个成员的单环、双环或三环饱和或不饱和杂环基团，R2代表氢原子或卤素原子，Y代表基团-O-、基团-CO-、基团-CH（OH）-或较低的烷基链，A代表[公式2] 其中，R3代表氢原子、较低的烷氧基或类似的基团，p代表1或2，R4代表咪唑基较低烷基基团或类似基团。